000144684 001__ 144684
000144684 005__ 20240229112634.0
000144684 0247_ $$2doi$$a10.1053/j.gastro.2019.08.023
000144684 0247_ $$2pmid$$apmid:31472152
000144684 0247_ $$2ISSN$$a0016-5085
000144684 0247_ $$2ISSN$$a1528-0012
000144684 0247_ $$2altmetric$$aaltmetric:66198709
000144684 037__ $$aDKFZ-2019-02126
000144684 041__ $$aeng
000144684 082__ $$a610
000144684 1001_ $$aSelby, Kevin$$b0
000144684 245__ $$aEffect of Sex, Age and Positivity Threshold on Fecal Immunochemical Test Accuracy: a Systematic Review and Meta-Analysis.
000144684 260__ $$aPhiladelphia, Pa. [u.a.]$$bSaunders$$c2019
000144684 3367_ $$2DRIVER$$aarticle
000144684 3367_ $$2DataCite$$aOutput Types/Journal article
000144684 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1577958568_14126$$xReview Article
000144684 3367_ $$2BibTeX$$aARTICLE
000144684 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144684 3367_ $$00$$2EndNote$$aJournal Article
000144684 500__ $$a157(6):1494-1505
000144684 520__ $$aQuantitative fecal immunochemical tests (FITs) for hemoglobin are commonly used for colorectal cancer (CRC) screening. We aimed to quantify the change in CRC and advanced adenoma detection and number of positive test results at different positivity thresholds and by sex and age.We searched MEDLINE and EMBASE, selecting articles of FIT for CRC detection in asymptomatic adults undergoing screening. We calculated sensitivity and specificity, as well as detected number of cancers, advanced adenomas, and positive test results at positivity thresholds ≤10 μg hemoglobin/g feces, 10 to ≤20 μg/g, 20 to ≤30 μg/g, and >30 μg/g. We also analyzed results from stratified by patient sex, age, and reference standard.Our meta-analysis comprised 46 studies with 2.4 million participants and 6478 detected cancers. Sensitivity for detection of CRC increased from 69% (95% CI, 63%-75%) at thresholds >10 μg/g and ≤20 μg/g to 80% (95% CI, 76%-83%) at thresholds ≤10 μg/g. At these threshold values, sensitivity for detection of advanced adenomas increased from 21% (95% CI, 18%-2%5) to 31% (95% CI, 27%-35%), whereas specificity decreased from 94% (95% CI, 93%-96%) to 91% (95% CI, 89%-93%). In 3 studies stratified by sex, sensitivity of CRC detection was 77% in men (95% CI, 75%-79%) and 81% in women (95% CI, 60%-100%) (P=.68). In 3 studies stratified by age groups, sensitivity of CRC detection was 85% for ages 50-59 years (95% CI, 71%-99%) and 73% for ages 60-69 years (95% CI, 71%-75%) (P=.10). All studies with colonoscopy follow up had similar sensitivity levels for detection of CRC to studies that analyzed 2-year registry follow-up data (74%; 95% CI, 68%-78% vs 75%; 95% CI, 73%-77%).In a meta-analysis of studies that analyzed detection of CRC and advanced adenomas at different FIT positivity thresholds, we found the sensitivity and specificity of detection to vary with positive cut-off value. It might be possible to decrease positive threshold values for centers with sufficient follow-up colonoscopy resources. More research is needed to precisely establish FIT thresholds for each sex and age subgroup.
000144684 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000144684 588__ $$aDataset connected to CrossRef, PubMed,
000144684 7001_ $$aLevine, Emma H$$b1
000144684 7001_ $$aDoan, Cecilia$$b2
000144684 7001_ $$0P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922$$aGies, Anton$$b3$$udkfz
000144684 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000144684 7001_ $$aQuesenberry, Charles$$b5
000144684 7001_ $$aLee, Jeffrey K$$b6
000144684 7001_ $$aCorley, Douglas A$$b7
000144684 773__ $$0PERI:(DE-600)1478699-0$$a10.1053/j.gastro.2019.08.023$$gp. S0016508519412432$$n6$$p1494-1505$$tGastroenterology$$v157$$x0016-5085$$y2019
000144684 909CO $$ooai:inrepo02.dkfz.de:144684$$pVDB
000144684 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000144684 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000144684 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000144684 9141_ $$y2019
000144684 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGASTROENTEROLOGY : 2017
000144684 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144684 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144684 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144684 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144684 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144684 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144684 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144684 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144684 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000144684 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144684 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bGASTROENTEROLOGY : 2017
000144684 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000144684 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000144684 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000144684 980__ $$ajournal
000144684 980__ $$aVDB
000144684 980__ $$aI:(DE-He78)C070-20160331
000144684 980__ $$aI:(DE-He78)C120-20160331
000144684 980__ $$aI:(DE-He78)L101-20160331
000144684 980__ $$aUNRESTRICTED